GSK to make $500m down payment on Chinese licensing deal worth up to $12bn
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay $500 million in upfront fees to Chinese drugmaker Hengrui Pharma as part of a wide-ranging collaboration to develop up to 12 experimental medicines in a deal worth up to a potential $12 billion. It is the latest move by the British giant to bolster its pipeline beyond 2031.
Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal
China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 other programmes to GlaxoSmithKline Intellectual Property (GSK) for $500 million upfront.
GSK's blood cancer drug gets EU approval for multiple myeloma
British drugmaker GSK said on Thursday the European Union has approved the company's blood cancer drug Blenrep for the treatment of relapsed or refractory multiple myeloma.
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.
GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt
The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.
GSK shares analysts get out the red pens after FDA knock-back wipes £3bn from drug maker's value
Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell 6% on Thursday, wiping more than £3bn from its market value, after a US advisory committee delivered a serious blow to the drugmaker's oncology ambitions. The Food and Drug Administration's (FDA) Oncology Drugs Advisory Committee (ODAC) voted against approving GSK's multiple myeloma drug Blenrep in two separate phase III trials.
GSK shares slide 6% after US panel rejects key cancer drug combination
GSK PLC (LSE:GSK, NYSE:GSK) shares dropped 6% on Friday, erasing over £3 billion from its market value, after a panel of experts advising the US Food and Drug Administration voted against the company's Blenrep drug combinations for advanced multiple myeloma. The advisory committee concluded that the benefits of Blenrep, also known as belantamab mafodotin-blmf, did not outweigh the risks at the proposed dosage used in clinical trials.
GSK shares fall after blood cancer drug likely headed for U.S. rejection
GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over eye-related side effects.
GSK gets red light from FDA cancer committee on Blenrep combos
An expert panel advising the US drug regulator has voted against GSK PLC's (LSE:GSK, NYSE:GSK) Blenrep drug combinations for patients with relapsed or refractory multiple myeloma. The US Food and Drug Administration's oncologic drugs advisory committee voted against the overall benefit/risk profile of belantamab mafodotin-blmf based on the proposed dosage used in clinical studies.
FDA Committee Votes Against GSK Blood Cancer Drug Blenrep
The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or refractory multiple myeloma who have previously received at least one line of therapy.
FDA staff raises eye damage concerns for GSK's blood cancer drug
The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in patients.
